Biogen Inc (BIIB) Quote - XNAS | Morningstar

Skip to Content

Is it the right time to buy or sell?

Find out with Morningstar Premium

Is it the right time to buy or sell?

Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Biogen Braces for Aducanumab Uncertainty in 2021; Shares Remain Undervalued

Sector Strategist Karen Andersen

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA | Feb 3, 2021

We're maintaining our $346 fair value estimate for Biogen following fourth-quarter results that were in line with our expectations, despite non-GAAP EPS guidance for 2021 that was below our expectations. After factoring in the costs and revenue potential from recent collaborations as well as the cost of launch preparations for aducanumab, we continue to think that the shares trade at a discount to their intrinsic value.

Read Full Analysis

Company Profile

Business Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Contact

225 Binney Street
Cambridge, MA, 02142

T +1 617 679-2000

Sector Healthcare

Industry Drug Manufacturers - General

Most Recent Earnings Dec 31, 2020

Fiscal Year End Dec 31, 2021

Stock Type Slow Growth

Employees 9,100

Related

Inside a Tough Year for Primecap

One of my favorite Vanguard fund managers fell well behind in 2020.

3 ETFs That Buy Low--But Not Too Low

These funds strike a balance between value and quality.

Healthcare Outlook: Coronavirus at Center Stage

And some undervalued stocks that capture our attention.

33 Undervalued Stocks for 2021

Here are our analysts' top ideas in each sector for the new year.

Susan Dziubinski

Quarter-End Insights

In Healthcare, Drugmakers and Managed-Care Firms Look Attractive

We don't expect major policy reforms now that the dust has settled on the elections.

Stock Strategist Industry Reports

Implementation of Trump's Drug-Pricing Orders Unlikely

We don't foresee any impact on pharma companies' moats or valuations.

Stock Analyst Update

Biogen's Alzheimer's Drug Doesn't Win Committee Support

We're lowering our fair value estimate for the wide-moat drug manufacturer.

10 High-Quality Stocks on Sale

Here's a peek at the most undervalued constituents of the Morningstar Wide Moat Focus Index--as well as names that have been added and cut.

Susan Dziubinski

24 Stocks for 2030

We think these companies are well positioned to benefit from one of five key trends during the next decade.

Susan Dziubinski

5 Bargains in Berkshire's Portfolio

We think these holdings look undervalued.

Susan Dziubinski

Stock Strategist Industry Reports

Innovation Supports Growth at Big Pharma/Big Biotech Companies

Moats and returns on invested capital look stable for companies with a solid list of pipeline drugs.

A Stock Fund Run by Standout Managers

Primecap Odyssey Growth's successful high-conviction multimanager system contributes to its Gold rating.

Stock Analyst Update

Drug Pricing Executive Orders Not Likely to Affect FVEs

We don’t expect these actions by President Trump to significantly affect our fair value estimates or moat ratings due to limited details, challenging implementation, and only minor impacts.

Investing Specialists

15 Companies Committed to Change

These companies achieve high Minority Empowerment Scores because they have demonstrated a strong commitment to diversity and inclusion.

Stock Strategist Industry Reports

Coronavirus Has Limited Impact on Big Pharma and Big Biotech

Moats, valuations, and dividends look attractive in the market pullback.

10 Undervalued Companies That Empower Women

These bargain stocks have demonstrated their commitment to gender equality.

Investing Specialists

Our Ultimate Stock-Pickers' Top 10 High-Conviction Purchases

Several funds see value in the technology, healthcare, and energy sectors.

4 Healthcare Stocks Attractive on Valuation and ESG Risk

Morningstar's Karen Andersen explains how ESG issues affect Big Pharma and biotech companies.

Stock Strategist Industry Reports

How ESG Risk Affects Pharma and Biotech Moats and Valuations

Morningstar and Sustainalytics offer complementary methodologies.

Stock Strategist

Reassuring Data Boosts Our Biogen Valuation

Details on Alzheimer's drug candidate are encouraging, but uncertainty remains.